Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-27T01:57:44.906Z Has data issue: false hasContentIssue false

Chapter 14 - Social and Private Costs of Dementia

Published online by Cambridge University Press:  26 May 2022

By
Patrick Cloos ,
Martin Knapp ,
Jeroen Luyten ,
Erik Schokkaert  and
Cheng Shi
Edited by
Mathieu Vandenbulcke ,
Rose-Marie Dröes  and
Erik Schokkaert
Mathieu Vandenbulcke
Affiliation:
KU Leuven, Belgium
Rose-Marie Dröes
Affiliation:
Amsterdam University Medical Centre
Erik Schokkaert
Affiliation:
KU Leuven, Belgium
Get access

Summary

We give an overview of the huge and increasing economic costs of dementia, both for the persons with dementia and for society as a whole. Public intervention is needed if we want to provide affordable and high-quality care to all persons with dementia. First, although an effective pharmaceutical cure for dementia would undoubtedly be a blockbuster drug for private companies, economic features of the production process of dementia medicines explain the relative underinvestment in private research. Second, there are no well-functioning private insurance markets for long-term care expenditures. Public intervention is needed to stimulate research, to finance care, to reduce inequalities in health and well-being, and address barriers to access to effective treatment and supportive care.

Keywords

cost of dementiasocio-economic gradient in dementiapharmaceutical researchpublic financing of dementia carewillingness-to-pay
Type
Chapter
Information
Dementia and Society , pp. 267 - 289
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Patterson, C. World Alzheimer Report 2018: The State of the Art of Dementia Research. London, Alzheimer’s Disease International, 2018.Google Scholar
Hurd, MD, Martorell, P, Delavande, A, Mullen, KJ, Langa, KM. Monetary costs of dementia in the United States. New England Journal of Medicine 2013; 368(14): 1326–34.CrossRefGoogle ScholarPubMed
Prince, M, Comas-Herrera, A, Knapp, M, Guerchet, M, Karagiannidou, M. World Alzheimer Report 2016: Improving Healthcare for People Living with Dementia. London, Alzheimer’s Disease International, 2016.Google Scholar
Hofmarcher, T, Lindgren, P, Wilking, N, Jönsson, B. The cost of cancer in Europe 2018. European Journal of Cancer 2020; 129: 41–9.CrossRefGoogle ScholarPubMed
Schaller, S, Mauskopf, J, Kriza, C, Wahlster, P, Kolominsky-Rabas, PL. The main cost drivers in dementia: A systematic review. International Journal of Geriatric Psychiatry 2015; 30(2): 111–29.CrossRefGoogle ScholarPubMed
Keogh-Brown, M, TarpJensen, H, Arrighi, M, Smith, RD. The impact of Alzheimer’s disease on the Chinese economy. EBioMedicine 4: 184–90.CrossRefGoogle Scholar
Rossor, M, Knapp, M. Can we model a cognitive footprint of interventions and policies to help to meet the global challenge of dementia? Lancet 2015; 386(9997): 1008–10.CrossRefGoogle Scholar
Knapp, M, Comas-Herrera, S, Wittenberg, R, Hu, B, King, D, Rehill, A, Adelaja, B. Scenarios of Dementia Care: What Are the Impacts on Cost and Quality of Life? London, PSSRU/CPEC, LSE, 2014.Google Scholar
Anderson, R, Knapp, M, Wittenberg, R, Handels, R, Schott, JM. Economic modelling of disease-modifying therapies in Alzheimer’s disease. Care Policy and Evaluation Centre, LSE, 2018.Google Scholar
Editorial. Dementia in the UK: Preparing the NHS for new treatments. Lancet 2018; 391: 1237.CrossRefGoogle Scholar
DiMasi, JA, Grabowski, HG, Hansen, RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics 2016; 47: 20–33.CrossRefGoogle ScholarPubMed
Wouters, OJ, McKee, M, Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. Journal of the American Medical Association 2020; 323(9): 844–53.Google Scholar
Scott, TJ, O’Connor, A, Link, AN, Beaulieu, TJ. Economic analysis of opportunities to accelerate Alzheimer’s disease research and development. Annals of the New York Academy of Sciences 2014; 1313(1): 17–34.CrossRefGoogle ScholarPubMed
Cummings, JL, Morstorf, T, Zhong, K. Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures. Alzheimer’s Research & Therapy 2014; 6(4): 37.CrossRefGoogle ScholarPubMed
Cummings, J, Reiber, C, Kumar, P. The price of progress: Funding and financing Alzheimer’s disease drug development. Alzheimer’s & Dementia (NY) 2018; 4: 330–43.Google Scholar
Cummings, J, Lee, G, Mortsdorf, T, Ritter, A, Zhong, K. Alzheimer’s disease drug development pipeline: 2017. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2017; 3(3): 367–84.Google Scholar
World Health Organization. Commission on Social Determinants of Health: Final Report [Internet]. Geneva, World Health Organization, 2008 [cited 2020 Feb 29]. Available from www.who.int/social_determinants/thecommission/finalreport/enGoogle Scholar
World Health Organization. World Report on Ageing and Health [Internet]. Geneva, World Health Organization, 2015 [cited 2020 Feb 29]. Available from www.who.int/life-course/publications/2015-ageing-report/enGoogle Scholar
Shah, A, Oommen, G, Wuntakal, B. Cross-cultural aspects of dementia. Psychiatry 2005; 4(2): 103–6.CrossRefGoogle Scholar
O’Connor, ML, McFadden, SH. A terror management perspective on young adults’ ageism and attitudes toward dementia. Educational Gerontology 2012 Sep 1; 38(9): 627–43.Google Scholar
Kivipelto, M, Ngandu, T, Laatikainen, T, Winblad, B, Soininen, H, Tuomilehto, J. Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-based study. Lancet Neurology 2006 Sep 1; 5(9): 735–41.CrossRefGoogle ScholarPubMed
Debette, S, Seshadri, S, Beiser, A, Au, R, Himali, JJ, Palumbo, C, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology [Internet]. 2011 [cited 2020 Mar 1]; 77(5). Available from https://n.neurology.org/content/77/5/461CrossRefGoogle ScholarPubMed
Mayer, F, Di Pucchio, A, Lacorte, E, Bacigalupo, I, Marzolini, F, Ferrante, G, et al. An estimate of attributable cases of Alzheimer disease and vascular dementia due to modifiable risk factors: The impact of primary prevention in Europe and in Italy. Dementia and Geriatric Cognitive Disorders Extra 2018 Feb 21; 8(1): 60–71.CrossRefGoogle ScholarPubMed
Cadar, D, Lassale, C, Davies, H, Llewellyn, DJ, Batty, GD, Steptoe, A. Individual and area-based socioeconomic factors associated with dementia incidence in England: Evidence from a 12-year follow-up in the English longitudinal study of ageing. JAMA Psychiatry 2018 Jul 1; 75(7): 723–32.CrossRefGoogle ScholarPubMed
Fratiglioni, L, Paillard-Borg, S, Winblad, B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurology 2004 Jun 1; 3(6): 343–53.CrossRefGoogle ScholarPubMed
Power, MC, Adar, SD, Yanosky, JD, Weuve, J. Exposure to air pollution as a potential contributor to cognitive function, cognitive decline, brain imaging, and dementia: A systematic review of epidemiologic research. NeuroToxicology 2016 Sep 1; 56: 235–53.CrossRefGoogle ScholarPubMed
Cooper, C, Lodwick, R, Walters, K, Raine, R, Manthorpe, J, Iliffe, S, et al. Inequalities in receipt of mental and physical healthcare in people with dementia in the UK. Age & Ageing 2017 May 1; 46(3): 393–400.Google ScholarPubMed
Cloos, P. Is there a pathological way of ageing? Questioning ‘Alzheimer’s disease’. Medicine Anthropology Theory 2017; 4(2): 60–9.Google Scholar
Chen, C, Zissimopoulos, JM. Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2018 Oct 5; 4: 510–20.Google ScholarPubMed
Anderson, NB, Bulatao, RA, Cohen, B, National Research Council (US) Panel on Race. Ethnic Differences in Dementia and Alzheimer’s Disease [Internet]. Washington, DC, National Academies Press, 2004 [cited 2020 Mar 2]. Available from www.ncbi.nlm.nih.gov/books/NBK25535Google Scholar
Lorenz, K, Freddolino, PP, Comas-Herrera, A, Knapp, M, Damant, J. Technology-based tools and services for people with dementia and carers: Mapping technology onto the dementia care pathway. Dementia 2019; 18(2): 725–74.CrossRefGoogle ScholarPubMed
Delavande, A, Hurd, MD, Martorell, P, Langa, KM. Dementia and out-of-pocket spending on health care services. Alzheimer’s and Dementia 2013; 9(1): 19–29.CrossRefGoogle ScholarPubMed
Kelley, AS, McGarry, K, Gorges, R, et al. The burden of health care costs for patients with dementia in the last 5 years of life. Annals of Internal Medicine 2015; 163(10): 729–36.CrossRefGoogle ScholarPubMed
Kaufman, JE, Gallo, W, Fahs, MC. The contribution of dementia to the disparity in family wealth between black and non-black Americans. Ageing and Society 2020; 40(2): 306–27.CrossRefGoogle Scholar
Charlesworth, A, Johnson, P. Securing the Future: Funding Health and Social Care to the 2030s. London, Institute for Fiscal Studies, 2018.Google Scholar
Baxter, K. Self-funders and social care: Findings from a scoping review. Research Policy and Planning 2016; 179–93.Google Scholar
Lum, T, Shi, C, Wong, G, Wong, K. COVID-19 and long-term care policy for older people in Hong Kong. Journal of Aging & Social Policy 2020; 1–7.CrossRefGoogle Scholar
World Health Organization. World Report on Ageing and Health. Geneva, World Health Organization, 2015.Google Scholar
Wittenberg, R, Knapp, M, Hu, B, et al. The costs of dementia in England. International Journal of Geriatric Psychiatry 2019; 34: 1095–1103.CrossRefGoogle ScholarPubMed
Wübker, A, Zwakhalen, SM, Challis, D, Suhonen, R, Karlsson, S, Zabalegui, A, Soto, M, Sas, K, Sauerland, D. Costs of care for people with dementia just before and after nursing home placement: Primary data from eight European countries. European Journal of Health Economics 2015; 16(7): 689–707.CrossRefGoogle ScholarPubMed
World Health Organization. Global Action Plan on the Public Health Response to Dementia 2017–2025. Geneva, World Health Organization, 2017.Google Scholar
Livingston, G, Manela, M, O’Keeffe, A, Rapaport, P, Cooper, C, Knapp, M, et al. Clinical effectiveness of START (STrAtegies for RelaTives) psychological intervention for family carers and the effects on cost of care for people with dementia: Six year follow-up of a randomised controlled trial. British Journal of Psychiatry 2019; 216(1): 35–42.CrossRefGoogle Scholar
Skinner, M, Lorentzen, H, Tingvold, L, Sortland, O, Andfossen, N, Iegermalm, M. Volunteers and informal caregivers’ contributions and collaboration with formal caregivers in Norwegian long-term care. Journal of Aging and Social Policy 2020; 1–26.CrossRefGoogle Scholar
Sharac, J, McCrone, P, Clement, S, Thornicroft, G. The economic impact of mental health stigma and discrimination: A systematic review. Epidemiologia e Psichiatria Sociale 2010; 19(3): 223–32.Google Scholar
World Health Organization. Dementia: A Public Health Priority. Geneva, World Health Organization, 2017.Google Scholar
Netten, A, Jones, K, Knapp, M, Fernandez, JL, Challis, D, Glendinnig, C, et al. Personalisation through individual budgets: Does it work and for whom? British Journal of Social Work 2012; 42(8): 1556–73.Google Scholar
Hatton, C, Waters, J. Older People and Personal Budgets: A Re-analysis of Data from the National Personal Budget Survey. London, Lancaster University and In Control, 2012.Google Scholar
George, KM, Lutsey, PL, Kucharska-Newton, A, Palta, P, Heiss, G, Osypuk, T, Folsom, AR Life course individual and neighborhood socioeconomic status and risk of dementia in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). American Journal of Epidemiology 2020 Oct; 189(10): 1134–42. doi.org/10.1093/aje/kwaa072CrossRefGoogle Scholar
Livingston, G, Sommerlad, A, Orgeta, V, Costafreda, SG, Huntley, J, Ames, D, et al. Dementia prevention, intervention, and care. Lancet 2017; 390: 2673–2734.CrossRefGoogle ScholarPubMed
Hyde, C, Peters, J, Bond, M, Rogers, G, Hoyle, M, Anderson, R, et al. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: Systematic review and economic model. Age and Ageing 2013; 42: 14–20.Google Scholar
Knapp, M, King, D, Romeo, R, Adams, J, Baldwin, A, Ballard, C, et al. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer’s disease (the DOMINO-AD trial). International Journal of Geriatric Psychiatry 2017; 32(12): 1205–16.CrossRefGoogle ScholarPubMed
Howard, R, McShane, R, Lindesay, J, Ritchie, C, Baldwin, A, Barber, R, et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO-AD) trial: Secondary and post-hoc analyses. Lancet Neurology 2015; 14: 1171–81.CrossRefGoogle ScholarPubMed
Pestieau, P, Ponthiere, G. Long term care insurance puzzle. CORE: Discussion Paper 2010/23, 2010.Google Scholar
Brown, J, Finkelstein, A. Insuring long-term care in the United States. Journal of Economic Perspectives 2011; 25: 119–42.Google Scholar
Courbage, C, Roudaut, N. Empirical evidence on long term care insurance purchase in France. Geneva Papers on Risk and Insurance 2008; 33: 645–58.Google Scholar
Finkelstein, A, McGarry, K. Multiple dimensions of private information: Evidence from the long-term care insurance market. American Economic Review 2006; 96: 938–58.CrossRefGoogle ScholarPubMed
Muir, T. Measuring Social Protection for Long-Term care: OECD Health Working Papers No. 93. Paris, OECD Publishing, 2017. http://dx.doi.org/10.1787/a411500a-en.Google Scholar
Drèze, JH, Pestieau, P, Schokkaert, E. Arrow’s theorem of the deductible and long-term care insurance. Economics Letters 2016; 148: 103–5.CrossRefGoogle Scholar
Basu, R. Willingness-to-pay to prevent Alzheimer’s disease: A contingent valuation approach. International Journal of Health Care Finance and Economics 2013; 13: 233–45.CrossRefGoogle ScholarPubMed
Neumann, P, Cohen, J, Hammitt, J, Concannon, T, Auerbach, H, Fang, C, Kent, D. Willingness-to-pay for predictive tests with no immediate treatment applications: A survey of US residents. Health Economics 2012; 21: 238–51.Google Scholar
Nocera, S, Bonato, D, Telser, H. The contingency of contingent valuation: How much are people willing to pay against Alzheimer’s disease? International Journal of Health Care Finance and Economics 2002; 2: 219–40.CrossRefGoogle ScholarPubMed
Nieboer, A, Koolman, X, Stolk, E. Preferences for long-term care services: Willingness to pay estimates derived from a discrete choice experiment. Social Science & Medicine 2010; 70: 1317–25.CrossRefGoogle ScholarPubMed
Negrin, MA, Pinilla, J, Leon, CJ. Willingness to pay for alternative policies for patients with Alzheimer’s disease. Health Economics, Policy and Law 2008; 3: 257–75.CrossRefGoogle ScholarPubMed
Gerves-Pinquie, C, Bellanger, M, Ankri, J. Willingness to pay for informal care in France: The value of funding support interventions for caregivers. Health Economics Review 2014; 4.CrossRefGoogle ScholarPubMed
König, M, Wettstein, A. Caring for relatives with dementia: Willingness-to-pay for a reduction in caregiver’s burden. Expert Review of Pharmacoeconomics and Outcomes Research 2002; 2: 535–47.CrossRefGoogle ScholarPubMed
Costa-Font, J. ‘Institutionalization aversion’ and the willingness to pay for home health care. Journal of Housing Economics 2017; 38: 62–9.CrossRefGoogle Scholar
Wong, G, Knapp, M. Should we move dementia research funding from a cure to its care? Expert Review of Neurotherapeutics 2020. doi: 10.1080/14737175.2020.1735364CrossRefGoogle Scholar
Mukadam, N, Anderson, R, Knapp, M, Wittenberg, R, Karagiannidou, M, Costafreda, SG, et al. Effective interventions for potentially modifiable risk factors for late-onset dementia: A costs and cost-effective modelling study. Lancet Healthy Longevity 2020: 1: e13–e20.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×